Insider transactions

David Charles Lubner

CIK 1572000 · Executive VP and CFO · last filed 2026-08-07

David Charles Lubner is an Executive VP and CFO who has filed 58 SEC Form 4 insider transactions across 11 companies since 2013. The most recent filing, for BRVE, was dated Aug 7, 2026. Across all open-market trades the lifetime net is −$780.1K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$0
Companies
11
Total Filings
58
Lifetime Open-Market Net
-$780.1K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
C/O TETRAPHASE PHARMACEUTICALS, INC.
480 ARSENAL STREET, SUITE 110
WATERTOWN, MA 02472
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Braveheart Bio, Inc. (BRVE) Delisted Director 55,555 — — $2.00M 2 2026-08-07
DYN Director 0 $15.10 $0 $0 9 2026-06-09
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director — $15.70 — $0 2 2026-06-03
Arcellx, Inc. (ACLX) Delisted Director 0 $115.07 $0 -$450.0K 7 2026-04-28
CARGO Therapeutics, Inc. (CRGX) Delisted Director — $4.47 — $0 4 2025-08-19
VOR Director — $18.29 — $0 5 2025-05-23
POINT Biopharma Global Inc. (PNT) Delisted Director 3,600 $12.50 $45.0K $24.7K 5 2023-12-27
Disc Medicine, Inc. (GMTX) Delisted Director — $13.50 — $0 5 2022-03-09
Ra Pharmaceuticals, Inc. (RARX) Delisted Executive VP and CFO 0 — — $0 5 2020-04-03
NITE Director 0 $39.11 $0 $0 2 2019-06-07
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted SVP and CFO 3,938 — — -$2.35M 11 2015-08-17

Recent Filings

58 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-07 Braveheart Bio, Inc. (BRVE) Delisted Mixed +55,555 $1000.0K EDGAR
2026-08-07 Braveheart Bio, Inc. (BRVE) Delisted Mixed +55,555 $1000.0K EDGAR
2026-06-09 DYN Grant (A) — $0 EDGAR
2026-06-03 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2026-04-28 Arcellx, Inc. (ACLX) Delisted Mixed −21,659 $0 EDGAR
2026-04-28 DYN Gift (G) −53,625 $0 EDGAR
2026-01-20 Arcellx, Inc. (ACLX) Delisted Notice (144) −15,000 -$1.03M EDGAR
2026-01-20 Arcellx, Inc. (ACLX) Delisted Mixed — -$412.3K EDGAR
2025-08-19 CARGO Therapeutics, Inc. (CRGX) Delisted Disp (D) — $0 EDGAR
2025-06-23 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 58
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.